Can We Use Plasma Fibronectin Levels as a Marker for Early Diabetic Nephropathy

Although increased plasma fibronectin (PF) levels have been found in diabetic patients with microalbuminuria, there is still controversy about its clinical implication for detecting early diabetic nephropathy. To evaluate the PF concentration as a possible marker for early diabetic nephropathy, thre...

Full description

Saved in:
Bibliographic Details
Published in:ENDOCRINE JOURNAL 1995, Vol.42(2), pp.301-305
Main Authors: OZATA, METIN, KURT, ISMAIL, AZAL, OMER, BOLU, EROL, CORAKCI, AHMET, BEYHAN, ZEYNEL, KARACA, LEVENT, GÜNDOGAN, MEHMET ALI
Format: Article
Language:English
Subjects:
Adult
Albuminuria - blood
Biomarkers
Diabetes mellitus
Diabetes Mellitus, Type 1 - blood
Diabetic Nephropathies - blood
Early diabetic nephropathy
Female
Fibronectin
Fibronectins - metabolism
Humans
Male
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although increased plasma fibronectin (PF) levels have been found in diabetic patients with microalbuminuria, there is still controversy about its clinical implication for detecting early diabetic nephropathy. To evaluate the PF concentration as a possible marker for early diabetic nephropathy, three groups of sex-and age-matched patients were studied I) 22 insulin dependent diabetic (IDDM) patients with microalbuminuria (mean age±SEM: 23.3±3.6 years, mean urinary albumin excretion rate (AER)±SEM: 47.1±39.5μg/min); II) 17 IDDM patients with normoalbuminuria (mean age: 23.4±4.4 years, mean AER: 7.8±2.1μg/min) and III) 20 healthy control subjects (mean age: 22.6±4.1 years, mean AER: 6.7±2.1μg/min). PF and urinary excretion of albumin were measured by an immunoturbidimetric method using commercially available kits (Boehringer Mannheim GMBH FRG, and Miles Lab., UK). The mean PF was significantly higher in the group with microalbuminuria (406.5±122.9μg/ml) than in the group with normoalbuminuria (295.6±96.9μg/ml, P
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.42.301